Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young-Sun | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yoo, Yang Jae | - |
dc.contributor.author | Kim, Tae Suk | - |
dc.contributor.author | Kang, Seong Hee | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Joo, Moon Kyung | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Lee, Beom Jae | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.accessioned | 2021-09-03T07:46:48Z | - |
dc.date.available | 2021-09-03T07:46:48Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-04 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83954 | - |
dc.description.abstract | Background and Aims: Although both corticosteroids and pentoxifylline are currently recommended drugs for the treatment of patients with severe alcoholic hepatitis, their effectiveness in reducing mortality remains unclear. In this systematic review, we aimed to evaluate the therapeutic and adverse effects of corticosteroids, pentoxifylline, and combination by using Cochrane methodology and therefore determine optimal treatment for severe alcoholic hepatitis. Methods: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from their inauguration until October 2015. Combinations of the following keywords and controlled vocabularies were searched: alcoholic hepatitis, corticosteroid, and pentoxifylline. Results: A total of 2639 patients from 25 studies were included. The treatment groups did not differ significantly in terms of overall mortality. Analysis of 1-month mortality revealed corticosteroid monotherapy reduced mortality compared with placebo (OR= 0.58; 95% CI, 0.34-0.98; P= 0.04), but pentoxifylline monotherapy did not. The mortality with dual therapy was similar to corticosteroid monotherapy (OR=0.91; 95% CI, 0.62-1.34; P= 0.63). However, dual therapy decreased the incidences of hepatorenal syndrome or acute kidney injury (OR= 0.47; 95% CI, 0.26-0.86; P= 0.01) and the infection risk (OR= 0.63; 95% CI, 0.41-0.97; P= 0.04) significantly more than corticosteroid monotherapy did. None of the treatments conferred any medium-term or long-term survival benefits in the present study. Conclusions: Dual therapy was not inferior to corticosteroid monotherapy and could reduce the incidence of hepatorenal syndrome or acute kidney injury and risk of infection. Therefore, dual therapy might be considered in treatment of patients with severe alcoholic hepatitis. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | SHORT-TERM SURVIVAL | - |
dc.subject | ACUTE KIDNEY INJURY | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | CONTROLLED TRIAL | - |
dc.subject | METHYLPREDNISOLONE THERAPY | - |
dc.subject | PREDNISOLONE | - |
dc.subject | IMPAIRMENT | - |
dc.subject | DIAGNOSIS | - |
dc.title | Treatment of Severe Alcoholic Hepatitis With Corticosteroid, Pentoxifylline, or Dual Therapy A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young-Sun | - |
dc.contributor.affiliatedAuthor | Kim, Hyun Jung | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Joo, Moon Kyung | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.contributor.affiliatedAuthor | Lee, Beom Jae | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Kim, Jae Seon | - |
dc.contributor.affiliatedAuthor | Park, Jong-Jae | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.contributor.affiliatedAuthor | Bak, Young-Tae | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.1097/MCG.0000000000000674 | - |
dc.identifier.scopusid | 2-s2.0-84987864033 | - |
dc.identifier.wosid | 000395991600011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL GASTROENTEROLOGY, v.51, no.4, pp.364 - 377 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL GASTROENTEROLOGY | - |
dc.citation.title | JOURNAL OF CLINICAL GASTROENTEROLOGY | - |
dc.citation.volume | 51 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 364 | - |
dc.citation.endPage | 377 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SHORT-TERM SURVIVAL | - |
dc.subject.keywordPlus | ACUTE KIDNEY INJURY | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CONTROLLED TRIAL | - |
dc.subject.keywordPlus | METHYLPREDNISOLONE THERAPY | - |
dc.subject.keywordPlus | PREDNISOLONE | - |
dc.subject.keywordPlus | IMPAIRMENT | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordAuthor | corticosteroid | - |
dc.subject.keywordAuthor | pentoxifylline | - |
dc.subject.keywordAuthor | severe alcoholic hepatitis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.